The Relationship Between Atherogenic Index of Plasma and No-reflow in Patients with Acute ST-segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention

Overview

Journal Int J Cardiovasc Imaging

Publisher Springer

Specialty Radiology

Date 2020 Jan 11

PMID 31919706

Citations 17

Authors

Muhammed Suleymanoglu

Ibrahim Rencuzogullari

Yavuz Karabag

Metin Cagdas

Mahmut Yesin

Ayca Gumusdag

Murat Cap

Murat Gok

Ibrahim Yildiz

Affiliations

Soon will be listed here.

Abstract

Because the phenomenon of no reflow has a poor prognosis in ST-segment elevation myocardial infarction (STEMI) patients and the atherogenic index of plasma (AIP) has been shown to be a strong predictor of coronary heart disease, we aimed to investigate the relationship between AIP and no-reflow in patients with acute STEMI who underwent primary percutaneous coronary intervention (PCI). A total of 763 consecutive STEMI patients (648 men; mean age 58 ± 12 years) who underwent primary PCI were recruited for this study. The patients were classified into a reflow group (n = 537) and a no-reflow group (n = 226) according to the postprocedural angiographic features of thrombolysis in the myocardial infarction flow of the infarct-related artery. The AIP value was significantly higher in the no-reflow group than in the reflow group [0.50 (0.38-0.65) vs. 0.39 (0.25-0.49) p < .001], and AIP was found to be an independent predictor of no-reflow development. The best cut-off value of AIP for predicting no-reflow was 0.54, with sensitivity of 46.02 and specificity of 84,73. In addition, the predictive power of AIP was greater than that of triglycerides and high-density lipoprotein cholesterol based on a receiver operator curve comparison. The AIP was independently associated with no-reflow in patients with STEMI after primary PCI. This might be a superior indicator compared to traditional lipid profiles.

Citing Articles

The association between the atherogenic index of plasma and all-cause mortality in patients undergoing peritoneal dialysis: a multicenter cohort study.

Hu Y, Yang L, Sun Z, Zhang X, Zhu X, Li J Lipids Health Dis. 2025; 24(1):91.

PMID: 40082960 PMC: 11905527. DOI: 10.1186/s12944-025-02510-z.

Association of triglyceride-glucose index with bone mineral density and fracture: a systematic review.

Yousefiasl M, Soltanattar A, Ezzatollahi Tanha A, Azami P, Alaei M, Alamdari A Diabetol Metab Syndr. 2025; 17(1):77.

PMID: 40038837 PMC: 11877733. DOI: 10.1186/s13098-025-01642-7.

Atherogenic index of plasma and coronary artery disease: a systematic review and meta-analysis of observational studies.

Assempoor R, Daneshvar M, Taghvaei A, Abroy A, Azimi A, Nelson J Cardiovasc Diabetol. 2025; 24(1):35.

PMID: 39844262 PMC: 11756160. DOI: 10.1186/s12933-025-02582-2.

Atherogenic index of plasma and the clinical outcome of patients with acute coronary syndrome: a meta-analysis.

Jiang S, Liu S, Xiao G, Liu K, Li J Ann Med. 2024; 57(1):2442532.

PMID: 39727274 PMC: 11703477. DOI: 10.1080/07853890.2024.2442532.

Association between triglyceride-glucose index and its correlation indexes and stress urinary incontinence in postmenopausal women: evidence from NHANES 2005-2018.

Huang X, Hu W, Li L Lipids Health Dis. 2024; 23(1):419.

PMID: 39716264 PMC: 11667865. DOI: 10.1186/s12944-024-02414-4.

References

Hashemi-Jazi M, Hosseini S, Gholamrezaei A . Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts. ARYA Atheroscler. 2018; 13(5):221-229. PMC: 5774794. View

Franz M, Bantle J, Beebe C, Brunzell J, Chiasson J, Garg A . Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care. 2002; 25(1):148-98. DOI: 10.2337/diacare.25.1.148. View

Sensoy B, Uzunget S, Acikgoz S, Sensoy N, Sen F, Acar B . Renal Dysfunction on Admission Predicts No-Reflow Phenomenon in Patients Undergoing Manual Thrombus Aspiration during Primary Percutaneous Coronary Intervention. Acta Cardiol Sin. 2016; 32(2):185-93. PMC: 4816917. DOI: 10.6515/acs20150424i. View

Zhan Y, Xu T, Tan X . Two parameters reflect lipid-driven inflammatory state in acute coronary syndrome: atherogenic index of plasma, neutrophil-lymphocyte ratio. BMC Cardiovasc Disord. 2016; 16:96. PMC: 4869274. DOI: 10.1186/s12872-016-0274-7. View

Cai G, Shi G, Xue S, Lu W . The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population. Medicine (Baltimore). 2017; 96(37):e8058. PMC: 5604669. DOI: 10.1097/MD.0000000000008058. View

Dobiasova M, Frohlich J . The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001; 34(7):583-8. DOI: 10.1016/s0009-9120(01)00263-6. View

Guerin M, Le Goff W, Lassel T, van Tol A, Steiner G, Chapman M . Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol. 2001; 21(2):282-8. DOI: 10.1161/01.atv.21.2.282. View

Schwartz E, Reaven P . Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis. Biochim Biophys Acta. 2011; 1821(5):858-66. DOI: 10.1016/j.bbalip.2011.09.021. View

Fajar J, Heriansyah T, Rohman M . The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis. Indian Heart J. 2019; 70 Suppl 3:S406-S418. PMC: 6309153. DOI: 10.1016/j.ihj.2018.01.032. View

10.

Bayramoglu A, Tasolar H, Kaya A, Tanboga I, Yaman M, Bektas O . Prediction of no-reflow and major adverse cardiovascular events with a new scoring system in STEMI patients. J Interv Cardiol. 2017; 31(2):144-149. DOI: 10.1111/joic.12463. View

11.

Karabag Y, Cagdas M, Rencuzogullari I, Karakoyun S, Artac I, Ilis D . Usefulness of The C-Reactive Protein/Albumin Ratio for Predicting No-Reflow in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Eur J Clin Invest. 2018; 48(6):e12928. DOI: 10.1111/eci.12928. View

12.

Zhou H, He X, Zhuang S, Wang J, Lai Y, Qi W . Clinical and procedural predictors of no-reflow in patients with acute myocardial infarction after primary percutaneous coronary intervention. World J Emerg Med. 2014; 5(2):96-102. PMC: 4129879. DOI: 10.5847/wjem.j.issn.1920-8642.2014.02.003. View

13.

Wan K, Zhao J, Huang H, Zhang Q, Chen X, Zeng Z . The association between triglyceride/high-density lipoprotein cholesterol ratio and all-cause mortality in acute coronary syndrome after coronary revascularization. PLoS One. 2015; 10(4):e0123521. PMC: 4399840. DOI: 10.1371/journal.pone.0123521. View

14.

Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne R . 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010; 55(21):2383-9. DOI: 10.1016/j.jacc.2009.12.054. View

15.

Thygesen K, Alpert J, Jaffe A, Chaitman B, White H, Katus H . Third universal definition of myocardial infarction. Circulation. 2012; 126(16):2020-35. DOI: 10.1161/CIR.0b013e31826e1058. View

16.

Balta S, Celik T, Ozturk C, Kaya M, Aparci M, Yildirim A . The relation between monocyte to HDL ratio and no-reflow phenomenon in the patients with acute ST-segment elevation myocardial infarction. Am J Emerg Med. 2016; 34(8):1542-7. DOI: 10.1016/j.ajem.2016.05.031. View

17.

Gibson C, de Lemos J, Murphy S, MARBLE S, McCabe C, Cannon C . Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001; 103(21):2550-4. DOI: 10.1161/01.cir.103.21.2550. View

18.

Niccoli G, Scalone G, Lerman A, Crea F . Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J. 2015; 37(13):1024-33. DOI: 10.1093/eurheartj/ehv484. View

19.

Anderson K, CASTELLI W, Levy D . Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987; 257(16):2176-80. DOI: 10.1001/jama.257.16.2176. View

20.

Deaton C, Sivarajan Froelicher E, Wu L, Ho C, Shishani K, Jaarsma T . The global burden of cardiovascular disease. Eur J Cardiovasc Nurs. 2011; 10 Suppl 2:S5-13. DOI: 10.1016/S1474-5151(11)00111-3. View